Susie Yoon1, Won-Pyo Hong1, Hyundeok Joo2, Dongyeon Jang1, Samina Park3, Ho-Jin Lee1. 1. Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Korea. 2. Seoul National University College of Medicine, Seoul, Korea. 3. Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul, Korea.
Abstract
OBJECTIVES: The association between adjuvant chemotherapy (AC) and chronic postoperative pain (CPP) after video-assisted thoracoscopic surgery (VATS) for lung cancer resection has not yet been reported. We, therefore, investigated the association between AC and the long-term incidence of CPP after VATS. METHODS: We retrospectively reviewed 3015 consecutive patients who underwent VATS for lung cancer between 2007 and 2016. The patients were divided into 2 groups: those who received (AC group) and those who did not receive (non-AC group) AC within 3 months after VATS. Propensity score analysis was performed to adjust for baseline differences between the 2 groups. The cumulative incidence of CPP at the intervals of 3 months, over 36 months, was compared before and after matching. A Cox proportional hazards regression analysis was used to investigate the predictors of CPP after VATS. RESULTS: We included and assessed 2222 patients in this study. Of these, 320 patients (14.4%) received AC within 3 months post-VATS. The cumulative incidence of CPP during 36 months post-surgery was significantly higher in the AC group than in the non-AC group, before and after matching (log-rank test; P = 0.002 and 0.027, respectively). Cox proportional hazards regression analysis also showed that AC was a significant risk factor for CPP (hazard ratio 1.62, 95% confidence interval 1.16-2.28; P = 0.005). CONCLUSIONS: Our results indicate that AC is an important risk factor for CPP after VATS. Further understanding of the risk factors for CPP may facilitate its prediction and treatment.
OBJECTIVES: The association between adjuvant chemotherapy (AC) and chronic postoperative pain (CPP) after video-assisted thoracoscopic surgery (VATS) for lung cancer resection has not yet been reported. We, therefore, investigated the association between AC and the long-term incidence of CPP after VATS. METHODS: We retrospectively reviewed 3015 consecutive patients who underwent VATS for lung cancer between 2007 and 2016. The patients were divided into 2 groups: those who received (AC group) and those who did not receive (non-AC group) AC within 3 months after VATS. Propensity score analysis was performed to adjust for baseline differences between the 2 groups. The cumulative incidence of CPP at the intervals of 3 months, over 36 months, was compared before and after matching. A Cox proportional hazards regression analysis was used to investigate the predictors of CPP after VATS. RESULTS: We included and assessed 2222 patients in this study. Of these, 320 patients (14.4%) received AC within 3 months post-VATS. The cumulative incidence of CPP during 36 months post-surgery was significantly higher in the AC group than in the non-AC group, before and after matching (log-rank test; P = 0.002 and 0.027, respectively). Cox proportional hazards regression analysis also showed that AC was a significant risk factor for CPP (hazard ratio 1.62, 95% confidence interval 1.16-2.28; P = 0.005). CONCLUSIONS: Our results indicate that AC is an important risk factor for CPP after VATS. Further understanding of the risk factors for CPP may facilitate its prediction and treatment.
Authors: Ellen L Poleshuck; Jennifer Katz; Carl H Andrus; Laura A Hogan; Beth F Jung; Dale I Kulick; Robert H Dworkin Journal: J Pain Date: 2006-09 Impact factor: 5.820
Authors: David S Ettinger; Wallace Akerley; Hossein Borghaei; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Ramaswamy Govindan; Frederic W Grannis; Stefan C Grant; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Feng-Ming Spring Kong; Mark G Kris; Lee M Krug; Rudy P Lackner; Inga T Lennes; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Mary C Pinder-Schenck; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Theresa A Shapiro; Scott J Swanson; Kurt Tauer; Douglas E Wood; Stephen C Yang; Kristina Gregory; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2013-06-01 Impact factor: 11.908
Authors: Jay Soong-Jin Lee; Hsou Mei Hu; Anthony L Edelman; Chad M Brummett; Michael J Englesbe; Jennifer F Waljee; Jeffrey B Smerage; Jennifer J Griggs; Hari Nathan; Jacqueline S Jeruss; Lesly A Dossett Journal: J Clin Oncol Date: 2017-10-19 Impact factor: 44.544
Authors: Jennifer L Glendenning; Yolanda Barbachano; Andy R Norman; David P Dearnaley; Alan Horwich; Robert A Huddart Journal: Cancer Date: 2010-05-15 Impact factor: 6.860
Authors: Winnie K W So; Gene Marsh; W M Ling; F Y Leung; Joe C K Lo; Maggie Yeung; George K H Li Journal: Eur J Oncol Nurs Date: 2009-09-05 Impact factor: 2.398